Novo Nordisk CEO Mike Doustdar said the company is hopeful the FDA will approve its next-generation obesity drug, CagriSema, by the end of 2026. The company could launch the drug in early 2027 and is reportedly already in production mode for the once-weekly injection.
CagriSema combines semaglutide with cagrilintide and has shown significant weight loss in clinical trials.
The update follows Novo Nordisk’s third-quarter results, reported on November 4. Strong demand for Wegovy, its weight-loss drug, and Ozempic, its diabetes treatment, led the company to improve its full-year sales outlook.